IL257379A - Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complex - Google Patents
Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complexInfo
- Publication number
- IL257379A IL257379A IL257379A IL25737918A IL257379A IL 257379 A IL257379 A IL 257379A IL 257379 A IL257379 A IL 257379A IL 25737918 A IL25737918 A IL 25737918A IL 257379 A IL257379 A IL 257379A
- Authority
- IL
- Israel
- Prior art keywords
- nlrp3
- diacerin
- inflammasome
- asc
- analogs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562206102P | 2015-08-17 | 2015-08-17 | |
| PCT/US2016/047272 WO2017031161A1 (en) | 2015-08-17 | 2016-08-17 | Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complex |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL257379A true IL257379A (en) | 2018-04-30 |
Family
ID=58051269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL257379A IL257379A (en) | 2015-08-17 | 2018-02-06 | Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complex |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10195170B2 (https=) |
| EP (2) | EP4147694A1 (https=) |
| JP (3) | JP6887987B2 (https=) |
| KR (1) | KR20180037261A (https=) |
| CN (1) | CN108349867B (https=) |
| AU (2) | AU2016308121A1 (https=) |
| BR (1) | BR112018003212A2 (https=) |
| CA (1) | CA2994987C (https=) |
| IL (1) | IL257379A (https=) |
| MX (1) | MX2018002049A (https=) |
| RU (1) | RU2729066C2 (https=) |
| TW (1) | TWI743047B (https=) |
| WO (1) | WO2017031161A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11840565B2 (en) | 2016-12-29 | 2023-12-12 | University Of Miami | Methods and compositions for treating virus-associated inflammation |
| RU2019123160A (ru) | 2016-12-29 | 2021-01-29 | Юниверсити Оф Майами | Способ модуляции активности инфламмасом и воспаления в легком |
| CN110177547B (zh) | 2017-01-18 | 2022-09-27 | 台睿生物科技股份有限公司 | 用于治疗炎症性肠病和肠结肠炎的组合物 |
| EP3634951B8 (en) | 2017-06-09 | 2024-08-21 | Zydus Lifesciences Limited | Novel substituted sulfoximine compounds |
| WO2019032672A1 (en) * | 2017-08-11 | 2019-02-14 | Olatec Therapeutics Llc | METHOD OF TREATING SCHNITZLER SYNDROME |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| SG11202013176VA (en) | 2018-07-03 | 2021-01-28 | Univ Miami | Compositions and methods for treating inflammasome related diseases or conditions |
| KR102075724B1 (ko) * | 2018-09-14 | 2020-02-10 | 한국원자력의학원 | 디아세레인을 유효성분으로 포함하는 항체의 종양 침투력 증진용 조성물 및 이의 용도 |
| IL283127B1 (en) * | 2018-11-14 | 2026-02-01 | Smilebiotek Zhuhai Ltd | Animal-based models, scanning methods, and methods of treating intraocular diseases or disorders |
| CN113226309B (zh) * | 2018-12-03 | 2024-10-29 | 珠海岐微生物科技有限公司 | 一种治疗年龄相关性黄斑变性的方法 |
| CN120208846A (zh) | 2019-01-14 | 2025-06-27 | 载度思生命科学有限公司 | 经取代的磺酰脲类衍生物 |
| CN109833292A (zh) * | 2019-02-23 | 2019-06-04 | 河南省人民医院 | 一种双醋瑞因滴眼液及其用途 |
| EP3956446A1 (en) | 2019-04-17 | 2022-02-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders |
| CN110179865A (zh) * | 2019-06-26 | 2019-08-30 | 广州中医药大学(广州中医药研究院) | 一种大黄蒽醌类成分的制备方法及其应用 |
| CN110787157A (zh) * | 2019-11-27 | 2020-02-14 | 中南民族大学 | 双醋瑞因在用于舒张预收缩的气管平滑肌及治疗哮喘中的应用 |
| JP7072260B2 (ja) * | 2019-12-27 | 2022-05-20 | 国立大学法人愛媛大学 | マックル・ウェルズ症候群の治療用医薬組成物 |
| US20230070129A1 (en) * | 2020-01-06 | 2023-03-09 | Seasun Therapeutics | Composition for preventing or treating macular degeneration, containing cell permeable nucleic acid complex as active ingredient |
| CN111358950A (zh) * | 2020-03-20 | 2020-07-03 | 厦门大学 | Caspase-1及ASC/Caspase-8作为靶点的应用 |
| WO2021198511A1 (en) | 2020-04-03 | 2021-10-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of sars-cov-2 infection |
| WO2022008597A1 (en) | 2020-07-08 | 2022-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of infectious diseases |
| WO2022084300A1 (en) | 2020-10-20 | 2022-04-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosis and monitoring form of coronavirus infection |
| CN115616216B (zh) * | 2021-07-15 | 2025-08-12 | 华南理工大学 | 抑制或阻断faah与nlrp3之间相互作用的制剂的用途 |
| WO2024261302A1 (en) | 2023-06-22 | 2024-12-26 | Institut National de la Santé et de la Recherche Médicale | Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020128317A1 (en) * | 2001-01-23 | 2002-09-12 | Laboratories Negma | Treatment of pathological conditions characterized by an increased IL-1 level |
| FR2842738B1 (fr) * | 2002-07-23 | 2006-02-10 | Negma Lerads | Utilisation d'une rheine pour la preparation d'un medicament pour le traitement de l'inflammation chronique, la prevention et le traitement du rejet des transplantations d'organes et de tissus |
| GB0404953D0 (en) * | 2004-03-04 | 2004-04-07 | Arakis Ltd | Pro-drugs |
| WO2010003092A1 (en) | 2008-07-03 | 2010-01-07 | University Of Massachusetts | Methods and compositions for reducing inflammation and treating inflammatory disorders |
| TWI473610B (zh) * | 2008-10-28 | 2015-02-21 | Twi Biotechnology Inc | 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物 |
| CN102060809B (zh) * | 2009-05-01 | 2015-05-20 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 一种大黄酸衍生物及其制备和用途 |
| KR101567925B1 (ko) | 2010-04-08 | 2015-11-10 | 티더블유아이 바이오테크놀로지 인코포레이티드 | 당뇨병 보조치료요법으로서 디아세레인을 사용하는 방법 |
| EP2598536A1 (en) * | 2010-07-29 | 2013-06-05 | Université de Genève | Process for the esterification of hyaluronic acid with hydrophobic organic compounds |
| CN103429236B (zh) * | 2011-03-11 | 2016-09-21 | 安成生物科技股份有限公司 | 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物 |
| US9707272B2 (en) | 2011-07-12 | 2017-07-18 | Universitat Zurich | Method for the treatment of acne by administering IL-1β antibody |
| US8652540B2 (en) * | 2012-06-04 | 2014-02-18 | Hong Kong Baptist University | Method of using rhein for treating fibrotic conditions and tumors |
| CN103110617A (zh) * | 2013-03-22 | 2013-05-22 | 中国人民解放军肾脏病研究所 | 一种双醋瑞因在制备治疗糖尿病肾病药物中的用途 |
| KR101486147B1 (ko) * | 2013-07-09 | 2015-01-23 | 주식회사 엘지생활건강 | Tslp 분비 저해능 및 이에 의한 알러지성 질환의 개선능을 가지는 조성물 |
| MX373702B (es) * | 2015-07-01 | 2020-05-07 | Twi Biotechnology Inc | Formulaciones topicas de diacereina o rheina y sus usos. |
-
2016
- 2016-08-17 US US15/238,950 patent/US10195170B2/en active Active
- 2016-08-17 BR BR112018003212-3A patent/BR112018003212A2/en not_active Application Discontinuation
- 2016-08-17 AU AU2016308121A patent/AU2016308121A1/en not_active Abandoned
- 2016-08-17 MX MX2018002049A patent/MX2018002049A/es unknown
- 2016-08-17 CA CA2994987A patent/CA2994987C/en active Active
- 2016-08-17 JP JP2018508748A patent/JP6887987B2/ja active Active
- 2016-08-17 EP EP22204951.2A patent/EP4147694A1/en not_active Withdrawn
- 2016-08-17 TW TW105126278A patent/TWI743047B/zh active
- 2016-08-17 EP EP16837725.7A patent/EP3337782A4/en not_active Withdrawn
- 2016-08-17 KR KR1020187006526A patent/KR20180037261A/ko not_active Ceased
- 2016-08-17 CN CN201680048207.3A patent/CN108349867B/zh active Active
- 2016-08-17 WO PCT/US2016/047272 patent/WO2017031161A1/en not_active Ceased
- 2016-08-17 RU RU2018109237A patent/RU2729066C2/ru active
-
2018
- 2018-02-06 IL IL257379A patent/IL257379A/en unknown
-
2021
- 2021-01-11 AU AU2021200117A patent/AU2021200117B2/en not_active Ceased
- 2021-05-18 JP JP2021083646A patent/JP2021121605A/ja active Pending
-
2023
- 2023-03-22 JP JP2023045240A patent/JP2023078360A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201717927A (zh) | 2017-06-01 |
| CN108349867A (zh) | 2018-07-31 |
| JP2018523687A (ja) | 2018-08-23 |
| AU2021200117A1 (en) | 2021-03-18 |
| RU2018109237A3 (https=) | 2019-12-31 |
| RU2729066C2 (ru) | 2020-08-04 |
| HK1254388A1 (zh) | 2019-07-19 |
| TWI743047B (zh) | 2021-10-21 |
| US10195170B2 (en) | 2019-02-05 |
| US20170049733A1 (en) | 2017-02-23 |
| JP2023078360A (ja) | 2023-06-06 |
| EP3337782A4 (en) | 2019-04-03 |
| EP3337782A1 (en) | 2018-06-27 |
| RU2018109237A (ru) | 2019-09-19 |
| BR112018003212A2 (en) | 2018-09-25 |
| WO2017031161A1 (en) | 2017-02-23 |
| CA2994987C (en) | 2023-09-26 |
| KR20180037261A (ko) | 2018-04-11 |
| MX2018002049A (es) | 2018-06-15 |
| AU2021200117B2 (en) | 2023-09-28 |
| AU2016308121A1 (en) | 2018-03-01 |
| CA2994987A1 (en) | 2017-02-23 |
| JP2021121605A (ja) | 2021-08-26 |
| JP6887987B2 (ja) | 2021-06-16 |
| EP4147694A1 (en) | 2023-03-15 |
| CN108349867B (zh) | 2021-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL257379A (en) | Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complex | |
| IL269642A (en) | Methods and compositions for enhancing health | |
| IL249061A0 (en) | Combination, composition, and method of administering the combination or composition to animals | |
| IL257978B (en) | Use of pasteurized akkermansia for treating metabolic disorders | |
| IL257279A (en) | Stable anti-ifnar1 formulation | |
| EP3302275A4 (en) | WELDING DISPLAY OF PHYSIOLOGICAL CONDITIONS | |
| LT3302565T (lt) | Kietos palbociklibo dozavimo formos | |
| LT3253865T (lt) | Metodai, skirti sustiprinti terapinių imuninių ląstelių veiksmingumą | |
| PL3186244T3 (pl) | Analogi dioksolanowe urydyny w leczeniu raka | |
| EP3329400A4 (en) | DISAMBING OF SEARCH QUESTIONS | |
| EP3406336A4 (en) | NANO FOIL OF CORE CASE STRUCTURE TYPE | |
| IL256206A (en) | Mct4 inhibitors for treating disease | |
| IL242971B (en) | Ventricular far field reduction | |
| PT3313418T (pt) | Composições de crioprecipitado e métodos de preparação das mesmas | |
| EP3399957A4 (en) | COMPOSITION FOR VIEWING | |
| KR101976358B9 (ko) | 로봇의 안전성 향상 방법 | |
| CL2015003493S1 (es) | Mueble. | |
| UY35747A (es) | Derivados sustituidos de fenilalanina | |
| EP3610851A4 (en) | COMPOSITION OF SKIN CLEANSING AGENT | |
| PL3487491T3 (pl) | Kompozycje do zwiększenia aktywności mózgu | |
| BR112017021527A2 (pt) | dentifrícios com base em cálcio para acentuar absorção de ingredientes ativos. | |
| EP3316879A4 (en) | TOPICAL DIACEREIN OR RHEIN FORMULATIONS AND USES THEREOF | |
| DK3352804T3 (da) | Artikel, der klæber til huden | |
| EP3359962A4 (en) | BLOOD PREPARATION AND PROFILING | |
| EP3383401A4 (en) | THIENOPYRIMIDINE DERIVATIVES AND USES THEREOF |